Press releases

2019-12-18 – Press release

Topas Therapeutics Announces First Patient Enrolled in Phase 1 Trial with TPM203 in Pemphigus Vulgaris

  • First program from the Topas platform to enter clinical testing
  • TPM203 is one of several proprietary programs being developed by Topas
  • Pemphigus vulgaris is an orphan indication that currently has no cure

read more …

2019-03-20 – Press release

Topas Therapeutics to Participate at Upcoming Industry and Scientific Conferences

Meet with Topas at following industry Events this spring

  • 2nd Antigen-Specific Immune Tolerance Drug Development Summit 2019. March 26-28, 2019, Boston, MA, USA
  • TReg Directed Therapies Summit, May 20-22, 2019, Boston, MA USA
  • 2019 German Biotech Days (Deutsche Biotechnologietage 2019), April 9-10, 2019, Würzburg, Germany
  • 20th Annual Bio€quity Europe, May 20-21, 2019, Barcelona, Spain

read more …

2018-09-27 – Press release

Topas Therapeutics to Participate at Upcoming Industry and Scientific Events

Meet with Topas at the following industry events this fall:

  • Sachs 18 th Annual Biotech in Europe Forum
  • BIO-Europe® 2018
  • Meetings around JP Morgan 36 th Annual Global Healthcare Conference
  • Immunology of Diabetes Society Congress 2018
  • Antigen-Specific Immune Tolerance Europe Conference

read more …

2018-04-24 – Press release

Topas Therapeutics and Boehringer Ingelheim Sign Multi-Year Collaboration and Option Agreement

  • Companies join forces in immune tolerance to tackle ADA (anti-drug antibodies)
  • Initial focus on next generation vector-based therapeutics
  • Boehringer Ingelheim is granted option to in-license several pre-clinical development candidates produced under the collaboration

read more …

2018-01-25 – Press release

Topas Therapeutics serves as exclusive translational partner for Collaborative Research Center focused on liver inflammation at University Medical Center Hamburg-Eppendorf

  • Funding for Collaborative Research Center (CRC) 841 at University Medical Center Hamburg-Eppendorf (UKE) extended for 4 years in the amount of nearly EUR 15 million.
  • Topas Therapeutics will act as exclusive partner for indication expansions and translation of research results into clinical development.

read more …